Method development and validation for the analysis of a new anti-cancer infusion solution via HPLC

✍ Scribed by Fabrizio Donnarumma; Margot Schober; Joachim Greilberger; Veronika Matzi; Jörg Lindenmann; Alfred Maier; Ralf Herwig; Reinhold Wintersteiger

• Publisher: John Wiley and Sons
• Year: 2010
• Tongue: English
• Weight: 176 KB
• Volume: 34
• Category: Article
• ISSN: 1615-9306
• DOI: 10.1002/jssc.201000574

✦ Synopsis

Abstract

A fast and simple HPLC method has been developed and validated for the quantification of a completely new anti‐cancer drug during the manufacturing process. The combination of four compounds including α‐ketoglutaric acid, hydroxymethylfurfural, N‐acetyl‐L‐methionine and N‐acetyl‐L‐selenomethionine, administered intravenously, is still in test phase but has already shown promising results in cancer therapy. HPLC separation was achieved on an RP‐18 column with a gradient system. However, the highly different concentrations of the compounds required a variation in the detection wavelength within one run. In order to produce a chromatogram where peaks were comparable on a similar range scale, detection at absorption maxima for the two most concentrated components was avoided. After optimization of the gradient program it was possible to detect all four substances within 14 min in spite of their strongly different chemical structure. The method developed was validated for accuracy, repeatability, reproducibility and robustness in relation to temperature and pH of buffer. Linearity as well as the limit of detection and quantification were determined. This HPLC method was found to be precise, accurate and reproducible and can be easily used for in‐line process control during the manufacture of the anti‐tumour infusion solution.